Association between the AUC0-24/MIC Ratio of Vancomycin and Its Clinical Effectiveness: A Systematic Review and Meta-Analysis

Impact of source of infection and vancomycin AUC0–24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia

(2014) N. Ghosh et al.   CLINICAL MICROBIOLOGY AND INFECTION

Vancomycin AUC/MIC Ratio and 30-Day Mortality in Patients with Staphylococcus aureus Bacteremia

(2013) Natasha E. Holmes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Are Vancomycin Trough Concentrations Adequate for Optimal Dosing?

(2013) Michael N. Neely et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A Stewardship Program’s Retrospective Evaluation of Vancomycin AUC24/MIC and Time to Microbiological Clearance in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis

(2013) Kristen M. Gawronski et al.   CLINICAL THERAPEUTICS

Vancomycin pharmacodynamics and survival in patients with methicillin-resistant Staphylococcus aureus-associated septic shock

(2013) Sheryl Zelenitsky et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Implementation of a protocol for administration of vancomycin by continuous infusion: pharmacokinetic, pharmacodynamic and toxicological aspects

(2013) Els Ampe et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Area under the concentration–time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia

(2013) Younghee Jung et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Benefits of Therapeutic Drug Monitoring of Vancomycin: A Systematic Review and Meta-Analysis

(2013) Zhi-Kang Ye et al.   PLoS One

The pharmacokinetics and pharmacodynamics of vancomycin in clinical practice: evidence and uncertainties

(2012) S. J. Vandecasteele et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Vancomycin AUC24/MIC Ratio in Patients with Complicated Bacteremia and Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus and Its Association with Attributable Mortality during Hospitalization

(2011) Jack Brown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets

(2011) R. Kullar et al.   CLINICAL INFECTIOUS DISEASES

Vancomycin Minimum Inhibitory Concentration and Outcome in Patients With Staphylococcus aureus Bacteremia: Pearl or Pellet?

(2011) T. L. Holland et al.   JOURNAL OF INFECTIOUS DISEASES

Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus

(2009) H. S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Relationship between Initial Vancomycin Concentration‐Time Profile and Nephrotoxicity among Hospitalized Patients

(2009) Thomas P. Lodise et al.   CLINICAL INFECTIOUS DISEASES

Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections

(2009) Christopher Giuliano et al.   Expert Review of Anti-Infective Therapy

Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists

(2008) M. Rybak et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY